Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04286607 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
A Phase 3 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 333
- Enrollment target
NCT04286607: Completed Phase 3 study, sponsored by Arcutis Biotherapeutics.
NCT04286607 is a Phase 3 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 333 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04286607, a Phase 3 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 333 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis
Primary Outcome
The occurrence of TEAEs and the occurrence of (Serious Adverse Events) SAEs
Interventions
- DRUG Topical roflumilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2024-01-22 |
| Phase | Phase 3 |
What the finished NCT04286607 record still lists
NCT04286607 is an interventional study that assigns participants to a tested intervention. The registered 333 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which Topical roflumilast is the first listed.
NCT04286607 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04286607 about?
NCT04286607 is a clinical study titled "Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis". This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis
What is the current status of trial NCT04286607?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 333 participants. The study started on 2020-02-12. Estimated completion is 2024-01-22.
What interventions are being tested in trial NCT04286607?
The interventions under investigation include: Topical roflumilast (DRUG).
Who is sponsoring clinical trial NCT04286607?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04286607's enrollment target sits among peer trials
333 1061st of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07395687 · 333 participants · Phase 2
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
- NCT05131672 · 334 participants · NA
Cast or Operation for Medial Epicondyle Fracture Treatment in Children
- NCT05131685 · 334 participants · NA
Distal Radius Interventions for Fracture Treatment
- NCT05546931 · 334 participants · NA
Mobile Health Program for Rural Hypertension
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI